UroGen Pharma Ltd. - Ordinary Shares (URGN)

Urogen Pharma (NASDAQ:URGN) reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow. The company said it expects to achieve profitability and generate positive cash flow in the fourth qu

The problem with a cancer that keeps coming back.

Repeat prescribers now fill half of ZUSDURI's base, yet holidays loom.

ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices.

Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.

Mark Schoenberg's final disposition under a pre-established Rule 10b5-1 plan follows 191% annual returns, leaving him with 119,763 shares worth $4.82 million.

Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.

Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

UroGen (URGN) Q1 2026 Earnings Transcript

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.

This clinical-stage biotech develops therapies for CML, NASH, and obesity.

UroGen (URGN) Q4 2025 Earnings Call Transcript

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

UroGen (URGN) Q3 2025 Earnings Call Transcript